{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:25:55Z","timestamp":1788020755767,"version":"build-2784847793"},"reference-count":105,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>The gene therapy approach for retinal disorders has been considered largely over the last decade owing to the favorable outcomes of the US Food and Drug Administration-approved commercial gene therapy, Luxturna. Technological advances in recent years, such as next-generation sequencing, research in molecular pathogenesis of retinal disorders, and precise correlations with their clinical phenotypes, have contributed to the progress of gene therapies for various diseases worldwide, and more recently in India as well. Thus, considerable research is being conducted for the right choice of vectors, transgene engineering, and accessible and cost-effective large-scale vector production. Many retinal disease-specific clinical trials are presently being conducted, thereby necessitating the collation of such information as a ready reference for the scientific and clinical community. In this article, we present an overview of existing gene therapy research, which is derived from an extensive search across PubMed, Google Scholar, and clinicaltrials.gov sources. This contributes to prime the understanding of basic aspects of this cutting-edge technology and information regarding current clinical trials across many different conditions. This information will provide a comprehensive evaluation of therapies in existing use\/research for personalized treatment approaches in retinal disorders.<\/jats:p>","DOI":"10.4103\/ijo.ijo_2902_23","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T08:07:50Z","timestamp":1722240470000},"page":"1091-1101","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Gene therapy for retinal diseases: From genetics to treatment"],"prefix":"10.4103","volume":"72","author":[{"given":"Ashish","family":"Khaparde","sequence":"first","affiliation":[{"name":"GROW Research Laboratory, Narayana Nethralaya Foundation, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace P","family":"Mathias","sequence":"additional","affiliation":[{"name":"GROW Research Laboratory, Narayana Nethralaya Foundation, Manipal, Karnataka, India"},{"name":"Manipal Academy of Higher Education, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Poornachandra","sequence":"additional","affiliation":[{"name":"Department of Vitreo Retina Services, Narayana Nethralaya, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M B","family":"Thirumalesh","sequence":"additional","affiliation":[{"name":"Department of Vitreo Retina Services, Narayana Nethralaya, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Shetty","sequence":"additional","affiliation":[{"name":"Department of Cornea and Refractive Surgery, Narayana Nethralaya, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkasubhra","family":"Ghosh","sequence":"additional","affiliation":[{"name":"GROW Research Laboratory, Narayana Nethralaya Foundation, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"R1-20260507","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.preteyeres.2010.03.004","article-title":"The molecular basis of human retinal and vitreoretinal diseases","volume":"29","author":"Berger","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"R3-20260507","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: An update","volume":"20","author":"Ginn","year":"2018","journal-title":"J Gene Med"},{"key":"R4-20260507","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1590\/s1679-45082017rb4024","article-title":"Gene therapy: Advances, challenges and perspectives","volume":"15","author":"Gon\u00e7alves","year":"2017","journal-title":"Einstein"},{"key":"R5-20260507","doi-asserted-by":"crossref","first-page":"89","DOI":"10.48175\/IJARSCT-7657","article-title":"Hemgenix as first gene therapy for treatment of Haemophilia B","volume":"2","author":"Navale","year":"2022","journal-title":"Int Adv Res Sci Commun Technol"},{"key":"R6-20260507","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/ICU.0000000000000660","article-title":"Gene therapy beyond Luxturna: A new horizon of the treatment for inherited retinal disease","volume":"31","author":"Prado","year":"2020","journal-title":"Curr Opin Ophthalmol"},{"key":"R7-20260507","doi-asserted-by":"crossref","first-page":"23505","DOI":"10.1073\/pnas.1910073116","article-title":"A single combination gene therapy treats multiple age-related diseases","volume":"116","author":"Davidsohn","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R8-20260507","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2014.05.001","article-title":"Causes and consequences of inherited cone disorders","volume":"42","author":"Roosing","year":"2014","journal-title":"Prog Retin Eye Res"},{"key":"R9-20260507","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.3390\/ijms20102542","article-title":"Genome editing as a treatment for the most prevalent causative genes of autosomal dominant retinitis pigmentosa","volume":"20","author":"Diakatou","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R10-20260507","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/13816810.2021.1913610","article-title":"Inherited retinal diseases are the most common cause of blindness in the working-age population in Australia","volume":"42","author":"Heath Jeffery","year":"2021","journal-title":"Ophthalmic Genet"},{"key":"R11-20260507","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/21678707.2018.1444476","article-title":"Gene therapy for the treatment of X-linked retinitis pigmentosa","volume":"6","author":"Martinez-Fernandez De La Camara","year":"2018","journal-title":"Expert Opin Orphan Drugs"},{"key":"R12-20260507","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N Engl J Med"},{"key":"R13-20260507","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum Gene Ther"},{"key":"R15-20260507","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1089\/hum.2018.156","article-title":"An AAV dual vector strategy ameliorates the stargardt phenotype in adult ABCA4\u2212\/\u2212 mice. Hum","volume":"30","author":"McClements","year":"2018","journal-title":"Gene Ther"},{"key":"R16-20260507","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ajo.2023.05.009","article-title":"First-in-human gene therapy trial of AAV8-hCARp.hCNGB3 in adults and children with CNGB3-associated Achromatopsia","volume":"253","author":"Michaelides","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"R17-20260507","doi-asserted-by":"crossref","first-page":"140555","DOI":"10.1016\/j.bbapap.2020.140555","article-title":"Deficit of human ornithine aminotransferase in gyrate atrophy: Molecular, cellular, and clinical aspects","volume":"1869","author":"Montioli","year":"2021","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"R18-20260507","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/APO.0000000000000209","article-title":"Genetics of bietti crystalline dystrophy","volume":"5","author":"Ng","year":"2016","journal-title":"Asia-Pacific J Ophthalmol"},{"key":"R19-20260507","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/IIO.0000000000000385","article-title":"Choroideremia gene therapy","volume":"61","author":"Lam","year":"2021","journal-title":"Int Ophthalmol Clin"},{"key":"R20-20260507","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: Initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"key":"R21-20260507","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/IIO.0000000000000364","article-title":"Gene therapies for the treatment of leber hereditary optic neuropathy","volume":"61","author":"Sahel","year":"2021","journal-title":"Int Ophthalmol Clin"},{"key":"R22-20260507","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","article-title":"Retinal AAV8-RS1 gene therapy for X-linked retinoschisis: Initial findings from a phase I\/IIa trial by intravitreal delivery","volume":"26","author":"Cukras","year":"2018","journal-title":"Mol Ther"},{"key":"R23-20260507","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/IIO.0000000000000378","article-title":"Retinal gene therapy for Usher syndrome: Current developments, challenges, and perspectives","volume":"61","author":"Dinculescu","year":"2021","journal-title":"Int Ophthalmol Clin"},{"key":"R24-20260507","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/TCRM.S338653","article-title":"Bardet-Biedl syndrome: Current perspectives and clinical outlook","volume":"19","author":"Melluso","year":"2023","journal-title":"Ther Clin Risk Manag"},{"key":"R25-20260507","article-title":"ALSA ventures launches novel gene therapy portfolio company Axovia therapeutics to treat ciliopathies","year":"2023"},{"key":"R26-20260507","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.ymthe.2020.06.029","article-title":"Gene therapy intervention in neovascular eye disease: A recent update","volume":"28","author":"Lin","year":"2020","journal-title":"Mol Ther"},{"key":"R27-20260507","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/jgm.1100","article-title":"Gene therapy clinical trials worldwide to 2007-An update","volume":"9","author":"Edelstein","year":"2007","journal-title":"J Gene Med"},{"key":"R28-20260507","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/jop.2021.0001","article-title":"Comprehensive preclinical assessment of ADVM-022, an intravitreal anti-VEGF gene therapy for the treatment of neovascular AMD and diabetic macular edema","volume":"37","author":"Gelfman","year":"2021","journal-title":"J Ocul Pharmacol Ther"},{"key":"R29-20260507","doi-asserted-by":"crossref","first-page":"11763.","DOI":"10.1038\/s41598-018-29726-7","article-title":"Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD","volume":"8","author":"Reid","year":"2018","journal-title":"Sci Rep"},{"key":"R30-20260507","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.3390\/ijms24043847","article-title":"RPE-directed gene therapy improves mitochondrial function in murine dry amd models","volume":"24","author":"Millington-Ward","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R31-20260507","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4155\/fmc.12.206","article-title":"Microvascular complications and diabetic retinopathy: Recent advances and future implications","volume":"5","author":"Barot","year":"2013","journal-title":"Future Med Chem"},{"key":"R32-20260507","doi-asserted-by":"crossref","first-page":"22.","DOI":"10.1007\/s11892-020-01308-w","article-title":"Updates on gene therapy for diabetic retinopathy","volume":"20","author":"Wang","year":"2020","journal-title":"Curr Diabetes Rev"},{"key":"R33-20260507","first-page":"133","article-title":"Diabetic macular edema","volume":"59","author":"Musat","year":"2015","journal-title":"Rom J Ophthalmol"},{"key":"R34-20260507","doi-asserted-by":"crossref","first-page":"963780","DOI":"10.3389\/fonc.2022.963780","article-title":"Retinoblastoma: Review and new insights","volume":"12","author":"Cruz-G\u00e1lvez","year":"2022","journal-title":"Front Oncol"},{"key":"R35-20260507","doi-asserted-by":"crossref","first-page":"eaat9321","DOI":"10.1126\/scitranslmed.aat9321","article-title":"Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01","volume":"11","author":"Pascual-Pasto","year":"2019","journal-title":"Sci Transl Med"},{"key":"R36-20260507","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1089\/hum.2022.159","article-title":"Update on viral gene therapy clinical trials for retinal diseases","volume":"33","author":"Cheng","year":"2022","journal-title":"Hum Gene Ther"},{"key":"R37-20260507","doi-asserted-by":"crossref","first-page":"906482","DOI":"10.3389\/fmed.2022.906482","article-title":"Advancing precision medicines for ocular disorders: Diagnostic genomics to tailored therapies","volume":"9","author":"Panikker","year":"2022","journal-title":"Front Med"},{"key":"R38-20260507","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3390\/cells12091280","article-title":"Corneal regeneration using gene therapy approaches","volume":"12","author":"Sarkar","year":"2023","journal-title":"Cells"},{"key":"R39-20260507","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"R40-20260507","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3390\/pharmaceutics14081605","article-title":"Lentiviral vectors for ocular gene therapy","volume":"14","author":"Arsenijevic","year":"2022","journal-title":"Pharmaceutics"},{"key":"R41-20260507","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1167\/iovs.64.7.39","article-title":"Gene therapy for retinal degenerative diseases: Progress, challenges, and future directions","volume":"64","author":"Drag","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R42-20260507","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3390\/biom11081135","article-title":"The ocular gene delivery landscape","volume":"11","author":"Sahu","year":"2021","journal-title":"Biomolecules"},{"key":"R43-20260507","doi-asserted-by":"crossref","first-page":"12584","DOI":"10.1073\/pnas.221364198","article-title":"Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk","volume":"98","author":"Vollrath","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R44-20260507","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.3390\/ijms23094883","article-title":"Retinitis pigmentosa: Progress in molecular pathology and biotherapeutical strategies","volume":"23","author":"Liu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R45-20260507","doi-asserted-by":"crossref","first-page":"e10258","DOI":"10.1002\/btm2.10258","article-title":"Viral vector-based gene therapies in the clinic","volume":"7","author":"Zhao","year":"2022","journal-title":"Bioeng Transl Med"},{"key":"R46-20260507","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2217\/fmb.10.100","article-title":"Retroviral vectors for gene therapy","volume":"5","author":"Maier","year":"2010","journal-title":"Future Microbiol"},{"key":"R47-20260507","doi-asserted-by":"crossref","first-page":"e23782","DOI":"10.1371\/journal.pone.0023782","article-title":"Retinal degeneration progression changes lentiviral vector cell targeting in the retina","volume":"6","author":"Calame","year":"2011","journal-title":"PLoS One"},{"key":"R48-20260507","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"Biodrugs"},{"key":"R49-20260507","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"R50-20260507","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1566523214666140302193709","article-title":"Basic biology of adeno-associated virus (AAV) vectors used in gene therapy","volume":"14","author":"Balakrishnan","year":"2014","journal-title":"Curr Gene Ther"},{"key":"R51-20260507","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J Virol"},{"key":"R52-20260507","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cobme.2018.09.004","article-title":"Adeno-associated virus (AAV) vectors: Rational design strategies for capsid engineering","volume":"7","author":"Lee","year":"2018","journal-title":"Curr Opin Biomed Eng"},{"key":"R53-20260507","doi-asserted-by":"crossref","first-page":"e6317","DOI":"10.7717\/peerj.6317","article-title":"Evaluation of AAV-DJ vector for retinal gene therapy","volume":"7","author":"Katada","year":"2019","journal-title":"Peer J"},{"key":"R54-20260507","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.3390\/cells11121881","article-title":"Immunogenicity of novel AAV capsids for retinal gene therapy","volume":"11","author":"Gehrke","year":"2022","journal-title":"Cells"},{"key":"R55-20260507","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol Ther"},{"key":"R57-20260507","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1146\/annurev-chembioeng-080615-034711","article-title":"Engineering delivery vehicles for genome editing","volume":"7","author":"Nelson","year":"2016","journal-title":"Annu Rev Chem Biomol Eng"},{"key":"R58-20260507","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/life13040903","article-title":"Non-viral carriers for nucleic acids delivery: Fundamentals and current applications","volume":"13","author":"Shtykalova","year":"2023","journal-title":"Life"},{"key":"R59-20260507","doi-asserted-by":"crossref","first-page":"R108","DOI":"10.1093\/hmg\/ddz130","article-title":"Has retinal gene therapy come of age? From bench to bedside and back to bench","volume":"28","author":"Trapani","year":"2019","journal-title":"Hum Mol Genet"},{"key":"R60-20260507","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1211\/0022357021701","article-title":"Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells","volume":"55","author":"Aukunuru","year":"2003","journal-title":"J Pharm Pharmacol"},{"key":"R61-20260507","first-page":"GE01","article-title":"Non viral vectors in gene therapy-An overview","volume":"9","author":"Ramamoorth","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"R62-20260507","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/hum.1993.4.6-733","article-title":"Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Hum","volume":"4","author":"Davis","year":"1993","journal-title":"Gene Ther"},{"key":"R63-20260507","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/bit.25971","article-title":"A cell engineering strategy to enhance supercoiled plasmid DNA production for gene therapy","volume":"113","author":"Hassan","year":"2016","journal-title":"Biotechnol Bioeng"},{"key":"R64-20260507","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/14712598.2021.1856365","article-title":"RNA therapeutics for retinal diseases","volume":"21","author":"Gemayel","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"R65-20260507","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jimd.12251","article-title":"Opportunities and challenges for antisense oligonucleotide therapies","volume":"44","author":"Kuijper","year":"2021","journal-title":"J Inherit Metab Dis"},{"key":"R66-20260507","doi-asserted-by":"crossref","first-page":"36.","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: Progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R67-20260507","doi-asserted-by":"crossref","first-page":"570917","DOI":"10.3389\/fncel.2020.570917","article-title":"Comparison of CRISPR\/Cas endonucleases for in vivo retinal gene editing","volume":"14","author":"Li","year":"2020","journal-title":"Front Cell Neurosci"},{"key":"R68-20260507","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1706193114","article-title":"CRISPR-Cas9 based treatment of myocilin-associated glaucoma","volume":"114","author":"Jain","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R69-20260507","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/gt.2012.2","article-title":"Zinc finger nucleases: Looking toward translation","volume":"20","author":"Palpant","year":"2013","journal-title":"Gene Ther"},{"key":"R70-20260507","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1073\/pnas.0611478104","article-title":"Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases","volume":"104","author":"Moehle","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R71-20260507","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2016.09.001","article-title":"In vivo genome editing as a potential treatment strategy for inherited retinal dystrophies","volume":"56","author":"Yanik","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"R72-20260507","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.apsb.2016.02.001","article-title":"Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: Current perspectives and future challenges","volume":"6","author":"Ha","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"R73-20260507","doi-asserted-by":"crossref","first-page":"45329","DOI":"10.1038\/srep45329","article-title":"Exosome-associated AAV2 vector mediates robust gene delivery into the murine retina upon intravitreal injection","volume":"7","author":"Wassmer","year":"2017","journal-title":"Sci Rep"},{"key":"R74-20260507","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1002\/jps.24588","article-title":"In vitro\/in vivo evaluation of dexamethasone-PAMAM dendrimer complexes for retinal drug delivery","volume":"104","author":"Yavuz","year":"2015","journal-title":"J Pharm Sci"},{"key":"R75-20260507","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jconrel.2021.05.035","article-title":"Systemic dendrimer nanotherapies for targeted suppression of choroidal inflammation and neovascularization in age-related macular degeneration","volume":"335","author":"Kambhampati","year":"2021","journal-title":"J Control Release"},{"key":"R76-20260507","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1167\/iovs.14-16250","article-title":"Systemic and intravitreal delivery of dendrimers to activated microglia\/macrophage in ischemia\/reperfusion mouse retina","volume":"56","author":"Kambhampati","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R77-20260507","article-title":"First patient enrolled in phase 1\/2 study of hydroxyl dendrimer imaging agent","year":"2023"},{"key":"R78-20260507","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00210-022-02287-3","article-title":"Nanomedicine and drug delivery to the retina: Current status and implications for gene therapy. Naunyn Schmiedebergs","volume":"395","author":"Tawfik","year":"2022","journal-title":"Arch Pharmacol"},{"key":"R79-20260507","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jconrel.2023.01.027","article-title":"Tailoring surface properties of liposomes for dexamethasone intraocular administration","volume":"354","author":"Al-Amin","year":"2023","journal-title":"J Control Release"},{"key":"R80-20260507","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3390\/pharmaceutics15051484","article-title":"Delivery systems in ocular retinopathies: The promising future of intravitreal hydrogels as sustained-release scaffolds","volume":"15","author":"Rafael","year":"2023","journal-title":"Pharmaceutics"},{"key":"R81-20260507","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41433-020-0770-y","article-title":"Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases","volume":"34","author":"Seah","year":"2020","journal-title":"Eye"},{"key":"R82-20260507","first-page":"19.","article-title":"Carbon-based nanomaterials for delivery of biologicals and therapeutics: A cutting-edge technology","volume":"7","author":"Mahor","year":"2021","journal-title":"C"},{"key":"R83-20260507","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.2147\/IJN.S394694","article-title":"Inflammatory genes associated with pristine multi-walled carbon nanotubes-induced toxicity in ocular cells","volume":"18","author":"Luo","year":"2023","journal-title":"Int J Nanomed"},{"key":"R84-20260507","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3390\/pharmaceutics14091973","article-title":"Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy","volume":"14","author":"Ren","year":"2022","journal-title":"Pharmaceutics"},{"key":"R85-20260507","doi-asserted-by":"crossref","first-page":"2213.","DOI":"10.1038\/s41598-018-19825-w","article-title":"Gene therapy for human glioblastoma using neurotropic JC virus-like particles as a gene delivery vector","volume":"8","author":"Chao","year":"2018","journal-title":"Sci Rep"},{"key":"R86-20260507","first-page":"1610.","article-title":"Expression of the human retina specific ABC transporter, ABCA4, in virus-like particles","volume":"53","author":"Biswas-Fiss","year":"2012","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R87-20260507","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1517\/17425247.2012.689285","article-title":"Cell-penetrating peptides for the delivery of nucleic acids","volume":"9","author":"Lehto","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"key":"R88-20260507","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.visres.2009.08.028","article-title":"Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin","volume":"50","author":"Johnson","year":"2010","journal-title":"Vis Res"},{"key":"R89-20260507","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1006\/mthe.2002.0806","article-title":"Intercellular trafficking of adenovirus-delivered hsv vp22 from the retinal pigment epithelium to the photoreceptors-implications for gene therapy","volume":"6","author":"Cashman","year":"2002","journal-title":"Mol Ther"},{"key":"R90-20260507","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev-bioeng-071813-104622","article-title":"Electroporation-based technologies for medicine: Principles, applications, and challenges","volume":"16","author":"Yarmush","year":"2014","journal-title":"Annu Rev Biomed"},{"key":"R91-20260507","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/17425247.2016.1121990","article-title":"Clinical potential of electroporation for gene therapy and DNA vaccine delivery","volume":"13","author":"Lambricht","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"R92-20260507","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1016\/j.vaccine.2015.05.005","article-title":"The site of administration influences both the type and the magnitude of the immune response induced by DNA vaccine electroporation","volume":"33","author":"Vandermeulen","year":"2015","journal-title":"Vaccine"},{"key":"R93-20260507","doi-asserted-by":"crossref","first-page":"120375","DOI":"10.1016\/j.lfs.2022.120375","article-title":"Gene therapy: Comprehensive overview and therapeutic applications","volume":"294","author":"Sayed","year":"2022","journal-title":"Life Sci"},{"key":"R94-20260507","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3390\/pharmaceutics15041111","article-title":"Hydrodynamic delivery: Characteristics, applications, and technological advances","volume":"15","author":"Suda","year":"2023","journal-title":"Pharmaceutics"},{"key":"R95-20260507","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3390\/cells9071744","article-title":"Hydrodynamics-based transplacental delivery as a useful noninvasive tool for manipulating fetal genome","volume":"9","author":"Nakamura","year":"2020","journal-title":"Cells"},{"key":"R96-20260507","doi-asserted-by":"crossref","first-page":"113998","DOI":"10.1016\/j.addr.2021.113998","article-title":"Ultrasonic particles: An approach for targeted gene delivery","volume":"179","author":"Walsh","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"R97-20260507","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.omtn.2022.01.006","article-title":"Ultrasound-mediated gene delivery of factor VIII plasmids for hemophilia A gene therapy in mice","volume":"27","author":"Song","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"R98-20260507","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2131\/jts.46.57","article-title":"Development challenges associated with rAAV-based gene therapies","volume":"46","author":"Bolt","year":"2021","journal-title":"J Toxicol Sci"},{"key":"R100-20260507","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40291-020-00475-6","article-title":"Voretigene neparvovec: A review in RPE65 mutation-associated inherited retinal dystrophy","volume":"24","author":"Kang","year":"2020","journal-title":"Mol Diagn Ther"},{"key":"R101-20260507","doi-asserted-by":"crossref","first-page":"a041307","DOI":"10.1101\/cshperspect.a041307","article-title":"Lessons learned from the development of the first FDA-approved gene therapy drug, voretigene neparvovec-rzyl","volume":"13","author":"Bennett","year":"2023","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R102-20260507","doi-asserted-by":"crossref","first-page":"e56661","DOI":"10.15252\/embr.202256661","article-title":"Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?: Can we avoid a catastrophic second valley of death?","volume":"24","author":"De Luca","year":"2023","journal-title":"EMBO Rep"},{"key":"R104-20260507","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/hum.2010.122","article-title":"Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequences","volume":"22","author":"Ghosh","year":"2011","journal-title":"Hum Gene Ther"},{"key":"R105-20260507","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41551-020-00656-y","article-title":"Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice","volume":"5","author":"Ling","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"R106-20260507","doi-asserted-by":"crossref","first-page":"13280","DOI":"10.3390\/ijms232113280","article-title":"Genetic aspects of age-related macular degeneration and their therapeutic potential","volume":"23","author":"Stradiotto","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R107-20260507","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/a-0811-5480","article-title":"Novel PDE6B mutation presenting with retinitis pigmentosa-A case series of three patients","volume":"236","author":"Palmowski-Wolfe","year":"2019","journal-title":"Klin Monbl Augenheilkd"},{"key":"R108-20260507","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/mt.2012.134","article-title":"Restoration of vision in the PDE6\u03b2-deficient dog, a large animal model of rod-cone dystrophy","volume":"20","author":"Petit","year":"2012","journal-title":"Mol Ther"},{"key":"R109-20260507","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00964382","article-title":"Ornithine delta-aminotransferase activity in retina and other tissues","volume":"9","author":"Rao","year":"1984","journal-title":"Neurochem Res"},{"key":"R110-20260507","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1016\/S0021-9258(19)50731-1","article-title":"Ornithine delta-aminotransferase mutations in gyrate atrophy. Allelic heterogeneity and functional consequences","volume":"267","author":"Brody","year":"1992","journal-title":"J Biol Chem"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2902_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:25:10Z","timestamp":1786724710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2902_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":105,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2902_23","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"2023-11-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}